Name

Youngr Labs

Legal name

Youngr Labs

Website

https://youngr.io

Company type

Private

Operating status

Operating

Ownership category

akta.pro rank

Product category

AI-driven longevity drug discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• AI longevity platform
• Single-cell RNA-seq
• Drug discovery AI
• Skin therapeutics
• Biological foundation models

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. B2B Technology Platform: The company provides AI-powered tools as a companion platform for scientists, ingredient innovators, and biotech companies to design anti-aging molecules and therapies. Revenue appears to derive from technology licensing and platform access to their AI models and data.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Youngr Labs develops AI Virtual Human Cells for longevity research, built on a proprietary in-vivo perturbational single-cell RNA-seq Atlas and a foundation model of human rejuvenation. The company enables scientists, ingredient innovators, and biotech companies to discover and design anti-aging small molecules, personalized active compounds, and skin-focused therapeutics, with prospective in-vivo validation and orthogonal evidence layers.

Product overview

Youngr Labs offers a unified platform centered on AI Virtual Human Cells for longevity research. The core product (AI Virtual Human Cells) is powered by the company's proprietary In Vivo Perturbational Single-Cell RNA-seq Atlas and Foundation Model of Human Rejuvenation. These integrated components enable scientists, ingredient innovators, and biotech companies to predict molecular effects on gene expression, identify novel biological targets, and discover next-generation anti-aging ingredients and therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

• AI Virtual Human Cells AI-driven virtual cellular models for longevity research that predict how human cells respond to perturbations, enabling scientists and biotech companies to test anti-aging interventions computationally before in-vivo validation.
• In-vivo Perturbational Single-Cell RNA-seq Atlas Proprietary atlas of human cellular responses generated from in-vivo perturbation experiments using single-cell RNA sequencing, serving as the foundational training data for the company's foundation model of human rejuvenation.
• Foundation Model of Human Rejuvenation AI foundation model trained on the company's perturbation Atlas to predict rejuvenation outcomes and prioritize anti-aging small molecule candidates for ingredient innovators and biotech pipeline partners.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Scale indicators1 record

Recent moves3 records

Expansion highlights4 records

Direct peers

• Recursion Pharmaceuticals: Operates one of the largest proprietary biological datasets generated through high-throughput wet-lab experiments, training AI models to discover therapeutics. Shares Youngr Labs' thesis that proprietary experimental data, not public static data, is the foundation for next-gen biological AI.
• Retro Biosciences: Longevity-focused biotech combining AI, cellular reprogramming, and autophagy research to develop therapeutics that extend healthy human lifespan. Directly comparable to Youngr Labs' longevity mission and AI-augmented therapeutic discovery approach.
• Insitro: AI/ML-driven drug discovery company combining proprietary high-throughput biology data with machine learning. Directly comparable to Youngr Labs' approach of using proprietary wet-lab data plus models to predict molecular effects on cells.
• NewLimit: AI-driven longevity biotech developing epigenetic reprogramming therapies to extend human healthspan. Directly comparable to Youngr Labs' mission of applying AI to discover therapeutics that restore cellular youth and reverse aging.

Broad incumbents

• Absci: Generative AI platform for biologics discovery that pairs proprietary wet-lab data with foundation models. Operates at a broader scale across antibody and protein design rather than skin-specific small molecules, but shares the proprietary-data + AI model thesis.
• Ginkgo Bioworks: Cell programming and biosecurity platform serving ingredient, biotech, and industrial customers with proprietary biological data assets. Comparable infrastructure-level play serving ingredient innovators and biotech, though at a much larger scale and broader scope.
• Altos Labs: Well-capitalized longevity biotech focused on cellular rejuvenation programming. Operates broadly across multiple organ systems and cell types rather than a single skin-focused platform, but pursues an overlapping thesis that aging is programmable and reversible.

Emerging players

• Cradle Bio: Uses generative AI to help biotech and consumer-product companies design novel proteins and molecules. Overlaps with Youngr Labs' value proposition of accelerating molecule and ingredient design for biotech and ingredient-innovator customers.
• Genesis Therapeutics: AI-native drug discovery company building foundation models for molecular design. Comparable to Youngr Labs' use of AI foundation models for predicting molecular effects, though focused on small-molecule drug discovery rather than skin/longevity specifically.

Others

• L'Oréal: Global beauty and skincare incumbent with active ingredient-innovation and longevity-skin programs and a track record of partnering with biotech startups. Relevant as a likely enterprise customer and design partner for Youngr Labs' ingredient-discovery value proposition, not as a direct AI competitor.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Youngr Labs